Tenet Healthcare

Tenet Healthcare Corp. engages in the provision of health care services. It operates through the following segments: Hospital Operations and Other, Ambulatory Care, and Conifer. The Hospital Operations and Other segment consists of acute care hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. The Ambulatory Care segment includes the operations of the USPI joint venture and the company's nine Aspen facilities in the United Kingdom. The Conifer segment offers healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities. The company was founded in 1975 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tenet Healthcare reports robust Q4 earnings, eyes growth opportunities

Tenet Healthcare's Q4 2022 performance showcased strong financial results, effective cash flow management, and positive growth projections for 2023.
While facing challenges such as cyber attacks and COVID-related disruptions, the company is focused on addressing contract labor costs and driving growth.
Opportunities for Tenet Healthcare include organic growth, strategic acquisitions, and enhancing operational efficiencies to drive future success.
Overall, Tenet Healthcare's performance, strengths, challenges, and opportunities position the company for continued growth and financial stability.

Tenet Healthcare excels in Q1 2023, eyes growth opportunities

Tenet Healthcare's Q1 2023 performance was robust, driven by strong results in USPI and the hospital segment.
Challenges include deferred procedures in certain healthcare services and managing labor shortages, but opportunities exist in ortho procedure growth and improved contract labor rates.
The company's focus on efficiency and partnership benefits bode well for future growth and margin improvement.

Tenet Healthcare reports robust Q2 earnings, raises full-year guidance

Tenet Healthcare's Q2 2023 performance reflects strong financial results across segments, with raised EBITDA guidance and solid cash flow generation.
While facing challenges in specific markets and increased CapEx, the company remains focused on sustaining profitability and enhancing shareholder value.
Opportunities lie in continued growth prospects, strategic investments, and operational improvements to drive long-term success and market expansion.
Overall, Tenet Healthcare's performance highlights resilience, strategic focus, and commitment to delivering value to shareholders amidst evolving market dynamics.

Tenet Healthcare excels in Q3, eyes growth in USPI specialties

Tenet Healthcare's Q3 2023 performance showcased strong financial results across its segments, with a focus on high acuity services and cost control.
While facing challenges such as rising medical fee costs and clinical denials, Tenet is strategically positioned to capitalize on growth opportunities in USPI specialties and margin expansion.
The company's emphasis on technology investments, labor optimization, and strategic decision-making underscores its commitment to sustainable growth and operational efficiency.
With an upwardly revised guidance for 2023 and plans for 2024 formulation, Tenet Healthcare is poised for continued success through prudent financial management and strategic initiatives.

Tenet Healthcare posts robust Q4 earnings, eyes growth opportunities

Tenet Healthcare delivered strong financial results in Q4 2023, with solid EBITDA figures across its segments and a positive outlook for 2024. While facing challenges such as regulatory impacts and labor management, the company remains focused on capital allocation priorities and growth opportunities in high acuity services and ASC diversification.

Tenet Healthcare excels in Q1 2024, eyes growth opportunities

Tenet Healthcare's Q1 2024 performance showcased strong financial results, with notable growth in adjusted EBITDA across segments and successful deleveraging.
The company's strategic initiatives, including divestitures, acquisitions, and focus on revenue optimization, position it well for future growth and profitability.
Despite challenges like margin dilution from recent acquisitions and calendar effects, Tenet's focus on enhancing operational efficiency and seizing growth opportunities remains key.

Tenet Healthcare excels in Q2, eyes growth through efficiency

Tenet Healthcare's Q2 2024 earnings call reflects strong financial performance, strategic initiatives, and a positive outlook for the full year, underpinned by revenue growth and operational enhancements.
While facing challenges in margin management and revenue mix sustainability, Tenet's focus on efficiency, debt reduction, and shareholder value creation positions it well for future growth.
The company's emphasis on operational efficiency, capacity utilization, and strategic investments underscores its commitment to delivering quality care, driving performance, and seizing growth opportunities.

Tenet Healthcare excels in Q3, eyes strategic growth opportunities

Tenet Healthcare's Q3 2024 performance reflects robust revenue growth, margin expansion, and increased guidance, underpinned by strong cash generation and strategic financial management.
While facing challenges in forecasting and capital allocation, Tenet's focus on operational efficiency and shareholder value creation positions it well for future growth and resilience.
By capitalizing on opportunities for strategic investments, debt optimization, and prudent capital deployment, Tenet can navigate industry complexities and drive sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tenet Healthcare Corp. engages in the provision of healthcare services. It operates through the Hospital Operations and Other, and Ambulatory Care segments. The Hospital Operations and Other segment is composed of acute care hospitals, ancillary outpatient facilities, urgent care centers, micro hospitals and physician practices. The Ambulatory Care segment includes the operations of the USPI joint venture and the company's nine Aspen facilities in the United Kingdom. The company was founded in 1969 and is headquartered in Dallas, TX.

Shares of Tenet Healthcare Corp. rose more than 6% in the extended session Tuesday after the company reported fourth-quarter results that were above Wall Street expectations and said it continues to experience "operational and financial challenges" amid the pandemic. Tenet said it earned $414 million, or $3.86 a share, in the quarter, versus a loss of $3 million, or 3 cents a share, in the year-ago period.

Tenet Healthcare stock rallies 6% after earnings beat

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended December 31, 2020 (4Q20). Ronald A. Rittenmeyer, Executive Chairman and Chief Executive Officer, stated, “In 2020, we along with so many others faced challenges we had never experienced in the history of our company. Our ability to perform under such challenging and constantly evolving circumstances underscores the strength of all of our colleagues within the Tenet enterpr

Tenet Reports Fourth Quarter 2020 Results; Announces Plan to Retire $478 million of Debt; Provides 2021 Financial Guidance

Larry Robbins (Trades, Portfolio)'s firm has revealed a reduction in its largest position, Tenet Healthcare Corp. (NYSE:THC), according to GuruFocus' Real-Time Picks.

Larry Robbins' Firm Sells More Tenet Healthcare Shares

The shares of Tenet Healthcare Corp (NYSE:THC)  are cooling off, two sessions removed from a five-year peak of $51.97.

Bull Signal Says THC Could Go Higher

Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare (THC) Earnings Expected to Grow: Should You Buy?

FRISCO, Texas--(BUSINESS WIRE)--Conifer Health Solutions, a subsidiary of Tenet Healthcare Corporation (NYSE: THC), announced today Dina Dunn will move into the company's chief human resources officer position, providing critical support on the company's growth and priority needs for the planned spinoff into a publicly traded company. “Dina is admired by her teams for her tremendous leadership and support, and she is recognized among peers and colleagues alike for her ability to execute efficie

Conifer Health Names Dina Dunn Chief Human Resources Officer

Crescent Point Energy

Ford Motor Company

Polaris

Top Ranked Momentum Stocks to Buy for February 1st

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) plans to report results for its fourth quarter ended December 31, 2020 after the market closes on Tuesday, February 9, 2021. The company will host a conference call the following morning, Wednesday, February 10, 2021, at 10:00 a.m. Eastern time (9:00 a.m. Central time). A live webcast and audio archive of the call may be accessed through the investor relations section of Tenet's website at www.tenethealth.com/investors. About Ten

Tenet to Report its Fourth Quarter Results on February 9

ABM Industries

Builders FirstSource

ManpowerGroup

Signet Jewelers

Brokers' evaluation should come in handy for investors. Evidently, broker-friendly stocks like ABM, Manpower (MAN), Builders FirstSource (BLDR), Signet Jewelers (SIG) and Tenet Healthcare (THC) are in focus.

5 Broker-Friendly Stocks in View Amid COVID-Led Economic Gloom

THC consists of 3 operating segments: Hospitals, Ambulatory Care, and the Conifer Segment. Management is executing on a clear roadmap of strategically high-grading the asset portfolio and over the long term (hopefully) de-levering the balance sheet.

Tenet Healthcare: Strategically Shifting Into A More Profitable Segment Of Healthcare

CVS Health

Sarepta Therapeutics

Thermo Fisher Scientific

Tenet Healthcare (NYSE: THC) shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60. Tenet is a Dallas-based healthcare provider organization operating a collection of hospitals (65) and many outpatient facilities, including ambulatory surgery centers, urgent care centers, freestanding imaging centers, freestanding emergency rooms/micro-hospitals, and physician practices across the United States.

Why Tenet, CVS, Thermo Fisher And Sarepta Are Moving Today

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) today announced the appointment of Cecil D. Haney to its Board of Directors, effective immediately. This appointment expands the Board to include 12 directors. Ron Rittenmeyer, Executive Chairman and CEO, said, “Cecil has demonstrated the true tenets of servant leadership throughout his incredibly distinguished career in the U.S. military. He is an extraordinary individual and leader who will complement our Board, particularly in

Tenet Appoints Cecil Haney to its Board of Directors

ArcBest

Avery Dennison

Installed Building Products

Mosaic

After in-depth research, brokers rate a company's stock. Hence, we select Tenet Healthcare (THC), Avery Dennison (AVY), ArcBest (ARCB), Mosaic Company (MOS) & Installed Building Products (IBP) as these witness ratings upgrade.

Upgraded Broker Ratings Make These 5 Stocks Worth a Look Now

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the 2021 J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, beginning at 10:00 a.m. Eastern time. A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet's website at www.tenethealth.com/investors. The audio archive will be available on Tenet's website for approximately 30 days. About Tenet Healthcare Tenet Healthcare Corporation (NYSE:

Tenet to Participate in the 2021 J.P. Morgan Healthcare Conference

Vivos Therapeutics

Marker Therapeutics Inc

Cyclo Therapeutics, Inc.

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and sales of cyclodextrins (CD) and related products for food, pharmaceutical, and other industries to be used in diagnostics and specialty drugs with continuing growth in research and new product development.

Why Cyclo, Vivos Therapeutics And More Are Moving Today

DaVita Inc. (NYSE: DVA) is focused on dialysis, which means that it is unlikely to get much of a boost from a reacceleration in volumes within health care, of which Tenet Healthcare Corp (NYSE: THC) is a key beneficiary, according to BofA Securities. The Health Care Analyst: Kevin Fischbeck downgraded DaVita from Buy to Neutral and raised the price target from $122 to $127.

Why BofA Is Upgrading Tenet Healthcare

Community Health Systems

HCA Healthcare

Universal Health Services

Hospital companies might feel the heat from price transparency rules, effective Jan 1, 2021.

Enforcement of Price Transparency Rules Puts Hospitals in a Fix

Tenet Healthcare's (THC) strategic measures and cost-controlling efforts are expected to drive its margins, which in turn, might inflate its share price.

Tenet Healthcare (THC) Up 126.9% in 6 Months: More Room for Rally?

Tenet Healthcare (THC) to restructure its ambulatory care business by axing the urgent care business and focusing on growing the ambulatory surgery business.

Tenet Healthcare (THC) to Rejig Business by Selling Urgent Care

Larry Robbins (Trades, Portfolio)'s Glenview Capital Management has revealed a reduction in its holding of Tenet Healthcare Corp. (NYSE:THC), according to GuruFoucus' Real-Time Picks, a Premium feature.

Larry Robbins' Firm Cuts Back Tenet Healthcare Holding

DALLAS--(BUSINESS WIRE)--Tenet Healthcare (NYSE: THC) and FastMed Urgent Care announced today that they have entered into a definitive agreement under which FastMed will purchase Tenet's urgent care platform, which is operated under the CareSpot and MedPost brands and managed by Tenet's United Surgical Partners International (USPI) subsidiary. FastMed is one of the nation's largest independent urgent care providers with 104 locations in North Carolina, Arizona and Texas. The transaction will ad

Tenet to Sell Urgent Care Platform to FastMed

The shares of Tenet Healthcare Corporation (NYSE:THC) up 4% at $41.41 at last check, after Deutsche Bank upgraded the stock to "buy" from "hold," with an added price-target hike to $69 from $28.

THC Ticks Higher After Deutsche Bank Upgrade

Tenet Healthcare (THC) to purchase 45 ambulatory surgery centers to aid its USPI ambulatory business, thus bolstering its position as a national musculoskeletal services leader in healthcare.

Tenet Healthcare (THC) to Buy 45 Ambulatory Surgery Centers

A big acquisition juiced the hospital operator's stock.

Why Tenet Healthcare Skyrocketed on Thursday

Greenwich Lifesciences

Immutep Ltd

Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metastatic breast cancer. Immutep is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases.

News for Tenet Healthcare Stock (THC)